Editorial comment on 'A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy' by Schmitt et al.
Hayward
R L
RL
Smyth
J F
JF
D000818:Animals; D017209:Apoptosis / Q000235:genetics; D019941:Cyclin-Dependent Kinase Inhibitor p16 / Q000235:genetics*; D004249:DNA Damage; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D016158:Genes, p53 / Q000235:genetics*; D016393:Lymphoma, B-Cell / Q000235:genetics*; D051379:Mice; D008822:Mice, Transgenic; D009368:Neoplasm Transplantation; D014162:Transfection; D016896:Treatment Outcome
D019941:Cyclin-Dependent Kinase Inhibitor p16